Do Thiazide Diuretics Increase the Risk of Skin Cancer? A Critical Review of the Scientific Evidence and Updated Meta-Analysis.


Journal

Current cardiology reports
ISSN: 1534-3170
Titre abrégé: Curr Cardiol Rep
Pays: United States
ID NLM: 100888969

Informations de publication

Date de publication:
27 07 2019
Historique:
entrez: 29 7 2019
pubmed: 29 7 2019
medline: 28 3 2020
Statut: epublish

Résumé

We reviewed the hypothesised mechanisms of skin cancerogenesis for thiazide diuretics; conducted an updated meta-analysis of studies focusing on their association with skin cancer risk; critically appraised the quality of available studies and identified knowledge gaps; and discussed implications for health professionals and patients. Thiazide diuretics possess well-described photosensitizing properties and a causal association with skin cancer is biologically plausible. The epidemiological evidence is stronger for squamous cell cancer; however, diversity in design among studies, methodological concerns potentially affecting the validity of results, and scarcity of data on dose-relation relationship suggest caution in drawing conclusions. Only few, unbalanced, and/or heterogeneous data exist to date for melanoma and basal cell cancer. Patients effectively treated with thiazide diuretics are currently not advised to stop treatment, but encouraged to limit exposure to sunlight and regularly check their skin. While endorsing these recommendations, we believe that well-designed studies are urgently needed to overcome persistent knowledge gaps.

Identifiants

pubmed: 31352643
doi: 10.1007/s11886-019-1183-z
pii: 10.1007/s11886-019-1183-z
doi:

Substances chimiques

Photosensitizing Agents 0
Sodium Chloride Symporter Inhibitors 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

92

Références

Semin Cutan Med Surg. 1999 Dec;18(4):274-84
pubmed: 10604793
Stat Med. 2002 Feb 28;21(4):589-624
pubmed: 11836738
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Eur J Cancer. 2005 Jan;41(1):28-44
pubmed: 15617989
Eur J Cancer. 2005 Jan;41(1):45-60
pubmed: 15617990
Eur J Cancer. 2005 Sep;41(14):2040-59
pubmed: 16125929
Am J Cardiovasc Drugs. 2008;8(6):373-418
pubmed: 19159124
Eur J Cancer. 2010 Sep;46(13):2467-72
pubmed: 20605443
Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2942-9
pubmed: 20861398
Int J Cancer. 2013 Jan 15;132(2):385-400
pubmed: 22532371
BMJ. 2012 Jul 24;345:e4757
pubmed: 22833605
Arch Intern Med. 2012 Sep 10;172(16):1246-51
pubmed: 22869299
Br J Dermatol. 2012 Aug;167 Suppl 2:1-13
pubmed: 22881582
J Invest Dermatol. 2013 Aug;133(8):1950-5
pubmed: 23344461
Br J Cancer. 2014 Apr 2;110(7):1855-61
pubmed: 24595003
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1545-54
pubmed: 25640031
Medicine (Baltimore). 2016 Jun;95(26):e4070
pubmed: 27368048
BMC Cancer. 2016 Dec 5;16(1):936
pubmed: 27919243
Drug Saf. 2017 Mar;40(3):249-255
pubmed: 27943160
Br J Dermatol. 2017 Jul;177(1):134-140
pubmed: 28369739
J Intern Med. 2017 Oct;282(4):322-331
pubmed: 28480532
Dermatol Pract Concept. 2017 Apr 30;7(2):1-6
pubmed: 28515985
Cancer Med. 2017 Oct;6(10):2203-2212
pubmed: 28879661
J Epidemiol. 2018 Jan 5;28(1):27-33
pubmed: 29176271
Biol Pharm Bull. 2017;40(12):2158-2165
pubmed: 29199239
J Am Acad Dermatol. 2018 Apr;78(4):673-681.e9
pubmed: 29217346
Crit Rev Oncol Hematol. 2018 Feb;122:1-9
pubmed: 29458778
JAMA Intern Med. 2018 Aug 1;178(8):1120-1122
pubmed: 29813157
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
J Am Acad Dermatol. 2019 Feb;80(2):460-465.e9
pubmed: 29913261
Curr Oncol Rep. 2018 Sep 24;20(11):87
pubmed: 30250984
Photochem Photobiol Sci. 2018 Dec 5;17(12):1885-1903
pubmed: 30283959
JAMA Intern Med. 2018 Oct 1;178(10):1425
pubmed: 30285130
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
J Hum Hypertens. 2019 Apr;33(4):257-258
pubmed: 30842544
Epidemiol Rev. 1987;9:1-30
pubmed: 3678409
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Br J Cancer. 1996 May;73(9):1126-31
pubmed: 8624275

Auteurs

Benedetta Bendinelli (B)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50141, Florence, Italy.

Giovanna Masala (G)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50141, Florence, Italy.

Giuseppe Garamella (G)

School of Specialization in Hygiene and Preventive Medicine, University of Florence, Florence, Italy.

Domenico Palli (D)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50141, Florence, Italy.

Saverio Caini (S)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50141, Florence, Italy. s.caini@ispro.toscana.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH